• Bufalin: Cardiotonics Driving Next-Gen Cancer Research Workf

  2026-04-21

  Bufalin, a high-purity cardiotonic steroid from APExBIO, is redefining apoptosis and cell differentiation assays in triple-negative breast cancer and hepatocellular carcinoma research. Explore workflow-ready protocols, advanced troubleshooting tips, and the translational power of STK33 targeting based on the latest mechanistic evidence.

• 25-Hydroxycholesterol Drives AMPK Activation in Immunosuppre

  2026-04-20

  Xiao et al. (2024) uncover a lysosome-centered pathway by which 25-hydroxycholesterol (25HC) activates AMPKα via the GPR155-mTORC1 complex in tumor-associated macrophages (TAMs), promoting immunosuppression and metabolic reprogramming. Targeting the CH25H/25HC axis enhances anti-tumor immune responses and synergizes with PD-1 blockade, offering new directions for immunometabolic intervention.

• Angiotensin (1-7): Protocol Optimization and Translational U

  2026-04-20

  Angiotensin (1-7) is redefining multi-system research as a Mas receptor agonist with robust anti-fibrotic, metabolic, and neuroprotective activities—now supported by advanced viral pathogenesis insight. This guide delivers actionable protocols, troubleshooting strategies, and comparative innovations to maximize the experimental potential of Angiotensin (1-7) from APExBIO.

• MLKL Polymerization Drives Lysosomal Membrane Permeabilizati

  2026-04-19

  Liu et al. demonstrate that MLKL polymerization at the lysosomal membrane is a central event in necroptosis, triggering lysosomal membrane permeabilization (LMP) and subsequent release of cathepsins—especially Cathepsin B—which drive cell death. This mechanistic insight refines our understanding of regulated necrotic cell death and highlights new experimental targets for the study and modulation of necroptosis.

• Murine RNase Inhibitor: Advanced RNA Integrity for Molecular

  2026-04-18

  Explore how Murine RNase Inhibitor empowers precise RNA degradation prevention in advanced molecular workflows. This in-depth article reveals unique oxidative resistance features and practical guidance for sensitive assay design.

• A-1331852: BCL-XL Inhibitor Workflows for Apoptosis Research

  2026-04-17

  A-1331852 sets a new standard for selective BCL-XL inhibition in apoptosis and cancer research, enabling robust, reproducible workflows that precisely target resistant tumor populations. This guide translates recent bench breakthroughs into protocol-ready strategies and troubleshooting tips for maximizing the compound’s impact in preclinical and translational settings.

• Bazedoxifene Targets IL-6/GP130 Signaling for Cancer Therapy

  2026-04-16

  This review highlights Bazedoxifene’s novel role as an inhibitor of the IL-6/GP130 signaling pathway, a central axis in cancer progression. Building on its clinical use as a selective estrogen receptor modulator for osteoporosis, the study details how Bazedoxifene impedes tumor-promoting pathways, suggesting its potential for drug repurposing in oncology.

• GANT61: GLI Inhibitor Workflows for Cancer Research Success

  2026-04-15

  GANT61 empowers researchers to precisely inhibit GLI-driven transcription in cancer models, overcoming key hurdles in Hedgehog pathway studies and immunotherapy resistance. This guide translates advanced mechanistic insight into actionable workflows, protocol parameters, and troubleshooting strategies to maximize your results.

• Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibi

  2026-04-14

  Anlotinib hydrochloride delivers superior inhibition of angiogenesis through precise multi-kinase targeting, empowering robust endothelial migration and tube formation assays. Its validated selectivity and high reproducibility make it a standout tool for dissecting tumor-driven vascularization at the bench.

• Causal Roles of CLEC5A and ISG20 in Atherosclerosis Progress

  2026-04-13

  Zhang et al. (2025) integrate Mendelian randomization with eQTL and functional assays to demonstrate that CLEC5A and ISG20 causally promote atherosclerosis, with ISG20 validated as a driver of macrophage lipid accumulation and inflammation. Their findings provide a foundation for targeting ISG20 in future therapeutic strategies and highlight advanced workflow designs for immunological research.

• ABT-888 (Veliparib): Strategic DNA Repair Inhibition in Onco

  2026-04-12

  This thought-leadership article explores the mechanistic rationale and translational strategies for using ABT-888 (Veliparib) as a potent PARP1/2 inhibitor to sensitize tumors to chemotherapy and radiation. The piece synthesizes recent evidence, including clinical and preclinical studies, and provides actionable guidance for researchers in colorectal and MSI tumor models. It differentiates itself by offering a synthesis of protocol optimization, competitive positioning, and outlook, referencing both APExBIO’s product integrity and the latest peer-reviewed insights.

• FGF19-ELF4 Axis Drives Metastasis in Colorectal Cancer via F

  2026-04-12

  The reference study identifies how FGF19-mediated upregulation of the transcription factor ELF4 promotes colorectal cancer metastasis through direct activation of FGFR4 and SRC. These mechanistic findings define a new feedback circuit driving aggressive disease and inform strategies for targeting metastatic progression.

• ABT-888 (Veliparib): Enhancing DNA Repair Inhibition Workflo

  2026-04-11

  ABT-888 (Veliparib) stands out as a potent PARP1/2 inhibitor for sensitizing MSI tumor models to chemotherapy and radiation. This article delivers actionable guidance for optimizing protocol parameters, overcoming experimental challenges, and leveraging the latest evidence on DNA repair inhibition in cancer research.

• Mitomycin C: Antitumor Antibiotic Workflows in Cancer Resear

  2026-04-11

  Mitomycin C stands apart as a robust antitumor antibiotic, enabling precise DNA replication inhibition and apoptosis signaling research. This in-depth guide demystifies experimental workflows, advanced applications, and real-world troubleshooting, empowering oncology labs to harness APExBIO's research-grade Mitomycin C for reproducible, high-impact results.

• Biotin-16-UTP: High-Efficiency Biotin-Labeled RNA Synthes...

  2026-04-10

  Biotin-16-UTP is a biotin-labeled uridine triphosphate analog enabling robust, high-specificity RNA labeling for molecular biology research. This reagent facilitates efficient RNA detection, purification, and interaction studies, including RNA-protein mapping in cancer models. Its ≥90% purity and compatibility with in vitro transcription workflows make it a cornerstone for sensitive, reproducible RNA research.

16288 records 1/1086 page Next 12345 下5页 Last page